Resources | Features | New study reveals that reversing al...
New study reveals that reversing albuminuria reduces cardiovascular events in patients with diabetic nephropathy
07 Sep 04
07 Sep 04
Summary
The RENAAL study, published in 2001 demonstrated that Merck's Losartan slows diabetic nephropathy and reduces the risk of heart failure. In a more recent analysis of the RENAAL database, researchers have shown that albuminuria predicts heart failure as well as other cardiovascular events and that the degree of success with which Losartan can reduce albumin levels is related to the extent of cardiovascular protection.The RENAAL study, published in 2001 demonstrated that Merck's Losartan slows diabetic nephropathy and reduces the risk of heart failure. In a more recent analysis of the RENAAL database, researchers have shown that albuminuria predicts heart failure as well as other cardiovascular events and that the degree of success with which Losartan can reduce albumin levels is related to the extent of cardiovascular protection.
(Editorial note: In depth reports on diabetic nephropathy and cardiovascular risk can be found at
(Editorial note: In depth reports on diabetic nephropathy and cardiovascular risk can be found at
